Nektar Therapeutics (NKTR) Long-Term Investments (2011 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Long-Term Investments of $163.0 million for Q1 2026, up 2001.24% year-over-year from $7.8 million in Q1 2025, and up 2934.69% quarter-over-quarter from $5.4 million in Q2 2025.
Nektar Therapeutics (NKTR) Long-Term Investments (2011 - 2026) Analysis & Trends
Nektar Therapeutics' Long-Term Investments history runs 14 years deep, the most recent figure standing at $163.0 million for Q1 2026.
- In Q1 2026, Long-Term Investments rose 2001.24% year-over-year to $163.0 million; the TTM figure through Mar 2026 stood at $163.0 million (up 2001.24% YoY), while the FY2024 annual figure was $12.2 million, down 52.69% from the prior year.
- Long-Term Investments for Q1 2026 stood at $163.0 million, up from $5.4 million in the prior quarter.
- The five-year high for Long-Term Investments was $163.0 million in Q1 2026, with the low at $4.5 million in Q3 2024.
- The 5-year median for Long-Term Investments is $15.8 million (2024), against an average of $32.1 million.
- The sharpest annual moves came in 2022 and 2026: Long-Term Investments sank 84.45% in 2022, then soared 2001.24% in 2026.
- Nektar Therapeutics' Long-Term Investments stood at $8.9 million in 2022, then jumped by 189.26% to $25.8 million in 2023, then plunged by 52.69% to $12.2 million in 2024, then tumbled by 56.04% to $5.4 million in 2025, then surged by 2934.69% to $163.0 million in 2026.
- Business Quant data shows NKTR's Long-Term Investments at $163.0 million in Q1 2026, $5.4 million in Q2 2025, and $7.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 162.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 162.99 Mn |
| Jun 30, 2025 | 5.37 Mn |
| Mar 31, 2025 | 7.76 Mn |
| Dec 31, 2024 | 12.22 Mn |
| Sep 30, 2024 | 4.54 Mn |
| Jun 30, 2024 | 19.41 Mn |
| Mar 31, 2024 | 36.78 Mn |
| Dec 31, 2023 | 25.83 Mn |
| Jun 30, 2022 | 8.93 Mn |
| Mar 31, 2022 | 37.36 Mn |
| Dec 31, 2021 | 64.83 Mn |
| Sep 30, 2021 | 34.22 Mn |
| Jun 30, 2021 | 57.40 Mn |
| Mar 31, 2021 | 96.09 Mn |
| Dec 31, 2020 | 136.66 Mn |
| Sep 30, 2020 | 197.72 Mn |
| Jun 30, 2020 | 172.17 Mn |
| Mar 31, 2020 | 185.90 Mn |
| Dec 31, 2019 | 279.12 Mn |
| Sep 30, 2019 | 231.08 Mn |